ECSP067067A - Derivados de quinazolinona útiles como antagonistas vanilloides - Google Patents
Derivados de quinazolinona útiles como antagonistas vanilloidesInfo
- Publication number
- ECSP067067A ECSP067067A EC2006007067A ECSP067067A ECSP067067A EC SP067067 A ECSP067067 A EC SP067067A EC 2006007067 A EC2006007067 A EC 2006007067A EC SP067067 A ECSP067067 A EC SP067067A EC SP067067 A ECSP067067 A EC SP067067A
- Authority
- EC
- Ecuador
- Prior art keywords
- quinazolinone derivatives
- vanilloid antagonists
- vanilloid
- antagonists
- quinazolinone
- Prior art date
Links
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000003839 salts Chemical group 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- -1 quinazolinone compound Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Cereal-Derived Products (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0412769.2A GB0412769D0 (en) | 2004-06-08 | 2004-06-08 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP067067A true ECSP067067A (es) | 2007-01-26 |
Family
ID=32696854
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2006007067A ECSP067067A (es) | 2004-06-08 | 2006-12-07 | Derivados de quinazolinona útiles como antagonistas vanilloides |
| ECSP12007067 ECSP12007067A (es) | 2004-06-08 | 2012-02-14 | Derivados de quinazolinona útiles como antagonistas vanilloides |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP12007067 ECSP12007067A (es) | 2004-06-08 | 2012-02-14 | Derivados de quinazolinona útiles como antagonistas vanilloides |
Country Status (29)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| GB0525068D0 (en) * | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| CN101506210A (zh) | 2006-08-23 | 2009-08-12 | 神经能质公司 | 2-苯氧基嘧啶酮类似物 |
| CA2668579A1 (en) * | 2006-11-06 | 2008-06-05 | Neurogen Corporation | Cis-cyclohexyl substituted pyrimidinone derivatives |
| AU2008277627B2 (en) | 2007-07-18 | 2011-10-27 | Novartis Ag | Synergistic combinations of VR-1 antagonists and COX-2 inhibitors |
| US8915362B2 (en) | 2008-10-08 | 2014-12-23 | Ultimed, Inc. | Sharps container |
| US8349852B2 (en) * | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| WO2011092290A1 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
| WO2011095450A1 (en) | 2010-02-02 | 2011-08-11 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| US8546416B2 (en) | 2011-05-27 | 2013-10-01 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
| BR112014026210A2 (pt) | 2012-05-03 | 2017-06-27 | Novartis Ag | derivados de sal l-malato de 2,7-diaza-espiro[4.5]dec-7-il e formas cristalinas dos mesmos como agonistas do receptor de grelina |
| WO2014138302A1 (en) * | 2013-03-05 | 2014-09-12 | University Of Notre Dame | Quinazolinone antibiotics |
| US10016425B2 (en) | 2016-11-03 | 2018-07-10 | King Saud University | Anti-ulcerative colitis compound |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| ES2979163T3 (es) | 2018-10-31 | 2024-09-24 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1 |
| JP6994061B2 (ja) | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| TWI878266B (zh) | 2019-02-15 | 2025-04-01 | 愛爾蘭商博士倫愛爾蘭有限公司 | 治療眼表痛之方法 |
| EP4431497A1 (en) | 2019-02-15 | 2024-09-18 | Bausch + Lomb Ireland Limited | Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| RU2755206C1 (ru) | 2020-05-20 | 2021-09-14 | Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) | Средство пролонгированного анальгетического действия и лекарственный препарат на его основе |
| WO2022029656A1 (en) | 2020-08-06 | 2022-02-10 | Novartis Ag | Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof |
| US20230416207A1 (en) * | 2020-11-17 | 2023-12-28 | Crystal Pharmatech Co., Ltd. | Crystalline forms of quinazolinone compound and process for preparing the same |
| UY39681A (es) | 2021-03-26 | 2022-10-31 | Novartis Ag | Derivados de ciclobutilo 1,3–sustituidos y sus usos |
| CN120112515A (zh) | 2022-09-21 | 2025-06-06 | 博士伦爱尔兰有限公司 | Trpv1拮抗剂的结晶多晶型形式及其制剂 |
| KR20250030194A (ko) | 2023-08-24 | 2025-03-05 | 코웨이 주식회사 | 출수 장치 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US220227A (en) * | 1879-10-07 | Improvement in stri klng-movements for clocks | ||
| US49728A (en) * | 1865-09-05 | Improvement | ||
| US82365A (en) * | 1868-09-22 | thompson | ||
| US95650A (en) * | 1869-10-12 | Improvement in machines for bending sheet-metal for cornices | ||
| DE239090C (enrdf_load_stackoverflow) | 1906-11-01 | |||
| US2749344A (en) | 1953-01-02 | 1956-06-05 | Burroughs Wellcome Co | Pyrimidine compounds |
| DE1224316B (de) | 1961-03-18 | 1966-09-08 | Beiersdorf & Co Ag P | Verfahren zur Herstellung von 2-Methyl-3-(o-aethylphenyl)-4-oxo-3, 4-dihydrochinazolin und dessen Salzen |
| DE1232152B (de) | 1962-06-27 | 1967-01-12 | Heyden Chem Fab | Verfahren zur Herstellung von 3-Phenylchinazolinon-(4)-derivaten |
| US3515787A (en) * | 1962-06-27 | 1970-06-02 | Squibb & Sons Inc | Compositions and methods for producing a muscle relaxing effect in an animal with 2,3 - substituted - 6 - amino-4-quinazolones |
| GB1003802A (en) | 1963-06-04 | 1965-09-08 | Searle & Co | Pyrimidinone derivatives |
| DE1280874B (de) | 1963-10-09 | 1968-10-24 | Boehringer Sohn Ingelheim | 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4) |
| US3317388A (en) | 1964-11-20 | 1967-05-02 | Wallace & Tiernan Inc | Methods for treating pain |
| US3864362A (en) | 1970-05-27 | 1975-02-04 | Chinoin Gyogyszer Es Vegyeszet | Iso flavones |
| BE793594A (fr) | 1972-01-03 | 1973-07-02 | Pfizer | Nouvelles 6,7-dimethoxyquinazolines utiles comme analgesiques et tranquillisants |
| GB1495305A (en) | 1975-09-12 | 1977-12-14 | Pfizer Ltd | 3-phenyl-4-oxo-4h-benzopyran derivatives |
| US4501755A (en) | 1981-05-01 | 1985-02-26 | Pennwalt Corporation | Isoflavones useful as anti-inflammatory agents |
| JPS59128376A (ja) * | 1983-01-13 | 1984-07-24 | Tanabe Seiyaku Co Ltd | キナゾリノン誘導体 |
| SU1262927A1 (ru) | 1985-01-09 | 1997-11-20 | Институт физико-органической химии и углехимии АН УССР | Способ получения 6-бром-5-метилимидазо(4,5-в)пиридина |
| JPS62201882A (ja) | 1985-11-18 | 1987-09-05 | Yamanouchi Pharmaceut Co Ltd | イソフラボン誘導体 |
| JPS62193605A (ja) | 1986-02-20 | 1987-08-25 | Toray Ind Inc | 半透性複合膜の製造方法 |
| ZA873745B (en) | 1986-06-04 | 1988-10-26 | Daiichi Seiyaku Co | Benzopyran derivatives |
| US5290780A (en) * | 1991-01-30 | 1994-03-01 | American Cyanamid Co. | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
| WO1992013535A1 (en) * | 1991-02-06 | 1992-08-20 | Research Corporation Technologies, Inc. | Anticonvulsant substituted quinazolones |
| US5958930A (en) | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
| US5284853A (en) | 1993-04-23 | 1994-02-08 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
| US5294617A (en) | 1993-04-23 | 1994-03-15 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
| EP0635263A3 (en) | 1993-06-28 | 1995-09-27 | American Cyanamid Co | Angiotensin II antagonists (AII) as inhibitors of the growth of adipose tissue. |
| HUT68558A (en) | 1993-07-20 | 1995-06-28 | Chinoin Gyogyszer Es Vegyeszet | Method for preparing isoflavon derivatives |
| US5620978A (en) | 1994-01-03 | 1997-04-15 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor |
| JPH07258224A (ja) | 1994-03-24 | 1995-10-09 | Dai Ichi Seiyaku Co Ltd | 二環性化合物 |
| US5756502A (en) * | 1994-08-08 | 1998-05-26 | Warner-Lambert Company | Quinazolinone derivatives as cholyecystokinin (CCK) ligands |
| NZ304291A (en) * | 1995-03-14 | 1999-01-28 | Novartis Ag | Trisubstituted phenyl derivatives, preparation and pharmaceutical compositions thereof |
| US5783577A (en) | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
| WO1997028118A1 (en) | 1996-02-05 | 1997-08-07 | Hoechst Celanese Corporation | Process for preparing anthranilic acids |
| AU712019B2 (en) | 1996-05-20 | 1999-10-28 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| FR2750862B1 (fr) | 1996-07-12 | 1998-10-16 | Dupin Jean Pierre | Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques |
| AU6908398A (en) | 1996-10-28 | 1998-05-22 | Versicor Inc | Fused 2,4-pyrimidinedione combinatorial libraries and biologically active fused 2,4-pyramidinediones |
| IT1289154B1 (it) | 1997-01-03 | 1998-09-29 | Chiesi Farma Spa | Derivati di isoflavone loro preparazione e loro impiego terapeutico |
| JPH10259176A (ja) | 1997-03-17 | 1998-09-29 | Japan Tobacco Inc | 血管新生阻害作用を有する新規アミド誘導体及びその用途 |
| US5948775A (en) | 1997-03-19 | 1999-09-07 | American Home Products Corporation | 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones |
| JP4444493B2 (ja) | 1997-08-20 | 2010-03-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | カプサイシン受容体およびカプサイシン受容体関連ポリペプチドをコードする核酸配列ならびにその使用 |
| WO1999037675A1 (en) | 1998-01-22 | 1999-07-29 | The Regents Of The University Of California | Nucleic acid sequences encoding capsaicin receptors |
| IL137719A0 (en) | 1998-02-25 | 2001-10-31 | Genetics Inst | Inhibitors of phospholipase enzymes |
| US6500853B1 (en) | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| ATE312812T1 (de) | 1999-02-22 | 2005-12-15 | Pacific Corp | Vanilloid-analoge die resiniferatoxin- pharmacophore enthalten als wirksame vanilloid rezeptor agonisten und analgetika, zusammensetzungen und ihre verwendung |
| GB9920912D0 (en) | 1999-09-03 | 1999-11-10 | Indena Spa | Novel derivatives of flavones,xanthones and coumarins |
| AU4742101A (en) | 2000-03-17 | 2001-10-03 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| AU2001280667B2 (en) | 2000-07-20 | 2007-08-02 | Neurogen Corporation | Capsaicin receptor ligands |
| JP5001505B2 (ja) * | 2000-08-21 | 2012-08-15 | 株式會社アモーレパシフィック | 新規チオウレア誘導体およびこれを含有する薬学的組成物 |
| FR2815033B1 (fr) | 2000-10-06 | 2003-09-05 | Negma Lab | Derives de 7-carboxy-flavones, porcede pour leur preparation et leur application en therapeutique |
| CA2431553A1 (en) | 2000-12-11 | 2002-10-24 | Tularik Inc. | Cxcr3 antagonists |
| SK11952003A3 (sk) | 2001-03-26 | 2004-03-02 | Novartis Ag | Deriváty pyridínu, spôsoby ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie |
| EP1414788A1 (en) * | 2001-07-31 | 2004-05-06 | Bayer HealthCare AG | Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists |
| GB0128499D0 (en) | 2001-11-28 | 2002-01-23 | Merck Sharp & Dohme | Therapeutic agents |
| IL147416A (en) * | 2001-12-31 | 2008-11-26 | Israel State | Combined modalities for improved cancer treatment |
| US7074805B2 (en) * | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| US7381730B2 (en) | 2002-03-15 | 2008-06-03 | Bristol-Myers Squibb Company | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators |
| WO2003106435A1 (en) * | 2002-06-18 | 2003-12-24 | Sankyo Company, Limited | Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof |
| KR100647932B1 (ko) | 2002-07-05 | 2006-11-23 | 에프. 호프만-라 로슈 아게 | 퀴나졸린 유도체 |
| EP1398032A1 (en) | 2002-09-10 | 2004-03-17 | PheneX Pharmaceuticals AG | 4-Oxo-quinazolines as LXR nuclear receptor binding compounds |
| GB0223730D0 (en) | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
| US20060052345A1 (en) | 2002-11-04 | 2006-03-09 | Nps Pharmaceuticals, Inc. | Quinazolinone compounds as calcilytics |
| CN1771235B (zh) | 2003-02-11 | 2010-04-28 | 弗奈利斯(剑桥)有限公司 | 异噁唑化合物 |
| JPWO2004078719A1 (ja) | 2003-03-06 | 2006-06-08 | 小野薬品工業株式会社 | インドール誘導体化合物およびその化合物を有効成分とする薬剤 |
| JP2006193426A (ja) | 2003-09-05 | 2006-07-27 | Sankyo Co Ltd | 置換された縮環ピリミジン−４（３ｈ）−オン化合物 |
| WO2005040112A1 (en) | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
| EP1687306A1 (en) * | 2003-11-14 | 2006-08-09 | MERCK SHARP & DOHME LTD. | Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1) |
| US7521455B2 (en) | 2004-02-13 | 2009-04-21 | Banyu Pharmaceutical Co. Ltd. | Fused ring 4-oxopyrimidine derivative |
| GB0412768D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| JP2009536608A (ja) | 2005-05-11 | 2009-10-15 | メルク シャープ エンド ドーム リミテッド | バニロイド−１受容体（ｖｒ１）の機能を調節する２，３−置換縮合二環式ピリミジン４−（３ｈ）−オン |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| AU2008277627B2 (en) | 2007-07-18 | 2011-10-27 | Novartis Ag | Synergistic combinations of VR-1 antagonists and COX-2 inhibitors |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
-
2004
- 2004-06-08 GB GBGB0412769.2A patent/GB0412769D0/en not_active Ceased
-
2005
- 2005-06-08 MX MXPA06014249A patent/MXPA06014249A/es active IP Right Grant
- 2005-06-08 JP JP2007526311A patent/JP4703650B2/ja not_active Expired - Lifetime
- 2005-06-08 HR HR20070577T patent/HRP20070577T4/hr unknown
- 2005-06-08 NZ NZ551630A patent/NZ551630A/en not_active IP Right Cessation
- 2005-06-08 KR KR1020067025788A patent/KR101018607B1/ko not_active Expired - Lifetime
- 2005-06-08 AU AU2005251476A patent/AU2005251476C1/en not_active Expired
- 2005-06-08 SG SG200903909-0A patent/SG153811A1/en unknown
- 2005-06-08 DE DE602005003128T patent/DE602005003128T3/de not_active Expired - Lifetime
- 2005-06-08 ES ES05750584T patent/ES2293584T5/es not_active Expired - Lifetime
- 2005-06-08 SI SI200530141T patent/SI1755606T2/sl unknown
- 2005-06-08 CN CN200580016187.3A patent/CN1956721B/zh not_active Expired - Lifetime
- 2005-06-08 RU RU2006146632/04A patent/RU2396261C2/ru active
- 2005-06-08 US US11/569,802 patent/US7960399B2/en not_active Expired - Lifetime
- 2005-06-08 AT AT05750584T patent/ATE376833T1/de active
- 2005-06-08 WO PCT/EP2005/006253 patent/WO2005120510A1/en active IP Right Grant
- 2005-06-08 DK DK05750584.4T patent/DK1755606T4/da active
- 2005-06-08 EP EP05750584A patent/EP1755606B2/en not_active Expired - Lifetime
- 2005-06-08 RU RU2010112450/04A patent/RU2449995C2/ru active
- 2005-06-08 KR KR1020107019024A patent/KR20100101017A/ko not_active Ceased
- 2005-06-08 CA CA2567821A patent/CA2567821C/en not_active Expired - Lifetime
- 2005-06-08 PT PT05750584T patent/PT1755606E/pt unknown
- 2005-06-08 BR BRPI0511933A patent/BRPI0511933B8/pt active IP Right Grant
- 2005-06-08 PL PL05750584T patent/PL1755606T5/pl unknown
-
2006
- 2006-11-20 ZA ZA200609634A patent/ZA200609634B/xx unknown
- 2006-11-23 IL IL179532A patent/IL179532A/en active IP Right Grant
- 2006-12-07 TN TNP2006000405A patent/TNSN06405A1/en unknown
- 2006-12-07 EC EC2006007067A patent/ECSP067067A/es unknown
- 2006-12-28 MA MA29565A patent/MA28685B1/fr unknown
-
2007
- 2007-01-08 NO NO20070122A patent/NO338181B1/no unknown
-
2008
- 2008-01-03 CY CY20081100014T patent/CY1107846T1/el unknown
-
2009
- 2009-11-06 AU AU2009233684A patent/AU2009233684A1/en not_active Abandoned
-
2011
- 2011-01-21 JP JP2011010997A patent/JP5400812B2/ja not_active Expired - Lifetime
- 2011-04-19 US US13/089,943 patent/US8211902B2/en not_active Expired - Lifetime
-
2012
- 2012-02-14 EC ECSP12007067 patent/ECSP12007067A/es unknown
- 2012-03-29 US US13/434,248 patent/US8809528B2/en not_active Expired - Lifetime
-
2014
- 2014-07-02 US US14/322,165 patent/US9102653B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP12007067A (es) | Derivados de quinazolinona útiles como antagonistas vanilloides | |
| ATE459622T1 (de) | Tropanverbindungen | |
| EA201790678A1 (ru) | Бициклические гетероарильные соединения | |
| UY28855A1 (es) | Derivados de la 1-amino-ftalazina su preparación y su uso en terapia | |
| ATE518824T1 (de) | Substituierte cyclohexylmethyl-derivate | |
| WO2006017054A3 (en) | Tricyclic-heteroaryl compounds useful as kinase inhibitors | |
| ATE445593T1 (de) | Acetylenderivate | |
| CR9058A (es) | Derivados de indol como inhibidores de la adenilato ciclasa soluble | |
| UY29040A1 (es) | Procedimiento de amino-tropano, su preparación y aplicación en terapéutica | |
| UY29859A1 (es) | Derivados de 1-amino-isiquinolina,su preparación y su aplicación terapéutica | |
| UY30235A1 (es) | Inhibidores de la adenilato ciclasa soluble | |
| CR9578A (es) | Inhibidores de la adenilato ciclasa soluble | |
| ATE455095T1 (de) | Vanilloidrezeptor trpv1-antagonisten | |
| ATE389634T1 (de) | Den vanilliod-trpv1-rezeptor antagonisierende sulfonamidoverbindungen | |
| UY30237A1 (es) | Inhibidores de la adenilato ciclasa soluble | |
| DOP2007000059A (es) | Inhibidores de la adenilato ciclasa soluble | |
| BRPI0506996A (pt) | compostos orgánicos | |
| DE602005024828D1 (de) | Rezeptors wirken | |
| ATE417040T1 (de) | Nitratester von phenylaminothiophen- essigsäurederivaten |